Crescent Biopharma Announces Grants of Inducement Awards Crescent Biopharma (Nasdaq: CBIO) announced inducement equity awards approved March 26, 2026. The independent Compensation Committee granted options to purchase a total of 35,325 ordinary shares to three non-executive employees under the 2025 Inducement Plan.The options have a 10-year term, an exercise price of $13.50 (Nasdaq close on March 26, 2026), and vest 25% after one year then monthly thereafter (1/48th per month), subject to continuous service and plan terms.

#CBIO Crescent Biopharma Announces Grants of Inducement Awards

www.stocktitan.net/news/CBIO/crescent-bioph...

Crescent Biopharma Announces Grants of Inducement Awards Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards totaling 45,675 shares to two non-executive employees, approved March 5, 2026 under its 2025 Employment Inducement Incentive Award Plan. The options carry a 10-year term and an exercise price of $11.33 (Nasdaq close on March 5, 2026).Vesting: 25% vests on the first anniversary of each employee’s start date, then 1/48th monthly thereafter, subject to continuous service and the plan and option agreement terms; grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

#CBIO Crescent Biopharma Announces Grants of Inducement Awards

www.stocktitan.net/news/CBIO/crescent-bioph...

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Crescent Biopharma (Nasdaq: CBIO) reported Q4 and full‑year 2025 results and business updates on Feb 26, 2026, highlighting a strategic partnership with Kelun‑Biotech, IND clearance and patient dosing for CR‑001, a global ASCEND Phase 1/2 trial, and a completed $185 million private placement that supports operations into 2028.

#CBIO Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CBIO/crescent-bioph...

Crescent Biopharma Announces Grants of Inducement Awards Crescent Biopharma (Nasdaq: CBIO) announced inducement option awards to three non-executive employees under its 2025 Employment Inducement Incentive Award Plan.The Board approved an aggregate of 129,626 options on December 13, 2025, and the options were granted on December 15, 2025. Each option has a 10-year term and an exercise price of $13.21, equal to the Nasdaq closing price on December 15, 2025. Vesting is 25% after the first anniversary of each employee’s start date, then monthly at 1/48th thereafter, subject to continuous service and the Inducement Plan terms.

#CBIO Crescent Biopharma Announces Grants of Inducement Awards

www.stocktitan.net/news/CBIO/crescent-bioph...

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Dec 4th - #YB #NA #MAMO #LASE #DRMA #CNTX #SYBX #SVCO #PLRX #NDRA #KITT #EKSO #CBIO #BBNX #ZKH #NOAH #GCO #ECVT #BBW - More: crystalequityresearch.com/leading-indi... - #smallcap

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics Crescent Biopharma (Nasdaq: CBIO) and Kelun-Biotech (6990.HK) announced a strategic oncology partnership to develop and commercialize Crescent’s CR-001 (PD-1 x VEGF bispecific) and Kelun’s SKB105 (ITGB6-directed ADC).Key terms: CR-001 and SKB105 are planned to enter Phase 1/2 monotherapy trials in Q1 2026; Kelun receives US$80M upfront plus up to US$1.25B in milestones and tiered royalties for SKB105 rights in Greater China; Crescent receives US$20M upfront plus up to US$30M in milestones and royalties for CR-001 rights outside Greater China. The collaboration includes monotherapy and combination development and cross‑territory exclusive commercial rights.

#CBIO Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

www.stocktitan.net/news/CBIO/kelun-biotech-...

Crescent Biopharma Announces Grants of Inducement Awards Crescent Biopharma (Nasdaq: CBIO) announced that its independent Compensation Committee approved inducement option awards for eight non-executive employees totaling 451,448 options, approved on November 14, 2025.The options have a 10-year term, an exercise price of $13.02 per share (Crescent's Nasdaq closing price on November 14, 2025), and vest 25% on the first anniversary of each employee's start date with the remainder vesting 1/48th monthly thereafter, subject to continuous service and the Inducement Plan terms. The grants were described as material to each employee's acceptance under Nasdaq Listing Rule 5635(c)(4).

#CBIO Crescent Biopharma Announces Grants of Inducement Awards

www.stocktitan.net/news/CBIO/crescent-bioph...

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights Crescent Biopharma (Nasdaq: CBIO) reported third quarter 2025 results and pipeline progress on Nov 6, 2025. Key clinical milestones include an IND submission for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025 to support a global Phase 1 trial starting in Q1 2026, with proof-of-concept data expected in H2 2026. Preclinical CR-001 data will be presented at SITC on Nov 7, 2025. Crescent also plans an IND for CR-002 (ADC) in mid-2026 and continues development of CR-003.Financials: cash of $133.3M as of Sept 30, 2025 (expected to fund operations through 2027), R&D expense of $20.3M, G&A expense of $5.5M, net loss of $24.6M ($1.27 per share) for Q3 2025, and ~19.6M shares outstanding.

#CBIO Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CBIO/crescent-bioph...

Trade Alerts, Thursday October 16, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Thu Oct 16th - #WHWK #WATT #SOND #REE #PRAX #KCHV #DTIL #CBIO #BMRA #ANY - More: crystalequityresearch.com/trade-alerts... - #smallcap

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights Crescent Biopharma (NASDAQ:CBIO) reported Q2 2025 financial results and significant corporate developments. The company completed a merger with GlycoMimetics and secured a $200 million private financing. Under new leadership, including CEO Joshua Brumm, Crescent is advancing its cancer therapeutics pipeline.The company's lead program, CR-001, a PD-1 x VEGF bispecific antibody, is progressing toward IND submission in Q4 2025, with proof-of-concept data expected in H2 2026. Two additional ADC programs, CR-002 and CR-003, are in development. Financial results show a cash position of $152.6 million, expected to fund operations through 2027, with a quarterly net loss of $21.8 million.

#CBIO Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CBIO/crescent-bioph...